Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of ...
The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13. March 10 marked its worst single-day decline in almost two years, plunging 4% as investor ...
Delcath Systems, Inc. (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted ...
Verus LLC is pleased to announce the appointment of Perry M. Cozzone and The Honorable Donald M. Remy to its Board of Managers. These distinguished leaders bring extensive experience in business ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cartesian Therapeutics (RNAC – Research Report) ...
Zacks Investment Research on MSN6h
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback